Abstract
Besides surgery, the therapeutic possibilities for the treatment of human gliomas include adoptive cellular immunotherapy, radioimmunotherapy, immunotherapy mediated by chemoimmunoconjugates and, more recently, bispecific monoclonal antibodies (biMAbs). Anti-CD3 x anti-tenascin (TN) is the first reagent of a number of biMAbs under investigation for prospective use in vivo to maximize the cell-mediated cytolytic potential of glioma patients. This biMAb originated from the fusion of 2 parental hybridomas, made resistant by retrovirus-mediated infection to the different metabolic drugs, geneticin and methotrexate, respectively. The resulting hybrid hybridomas were selected on the basis of the double specificity for CD3 and TN, cloned several times and grown under continuous metabolic pressure. The different families of recombinant antibodies were then purified by high-pressure liquid chromatography on hydroxylapatite columns. Immunohistochemical studies on tumor specimens of different origin and histotype have shown that the selected biMAb presented a distribution pattern similar to that of the parental anti-TN MAb, maintaining the same staining homogeneity and intensity. Moreover, the mitogenic activity of anti-CD3 x anti-TN biMA...Continue Reading
References
Jan 1, 1992·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M T JenningsJ R Shapiro
Apr 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·E D LaywellD A Steindler
Sep 11, 1992·Brain Research·W J RettigP Garin-Chesa
Sep 1, 1992·The Journal of Clinical Investigation·P NisticòA Anichini
Jul 1, 1992·Journal of Neuro-oncology·S K ObukhovP C Beverely
May 22, 1992·Journal of Chromatography·L TarditiM Mariani
Apr 1, 1991·International Journal of Cancer. Journal International Du Cancer·P G NataliL Zardi
Dec 15, 1991·Journal of Immunological Methods·P Matzinger
Feb 17, 1990·Lancet·T NittaS Ishii
Apr 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·L B DeMonteF Malavasi
Mar 1, 1989·The Journal of Cell Biology·M A Bourdon, E Ruoslahti
Apr 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·F MalavasiG Camussi
Jan 1, 1987·Annual Review of Cell Biology·G R Martin, R Timpl
Aug 1, 1994·Human Immunology·A FunaroF Malavasi
Oct 1, 1993·Current Opinion in Cell Biology·H P Erickson
Sep 1, 1994·Cell Calcium·M MurgiaL Chieco Bianchi
Mar 1, 1994·Immunology Today·F MalavasiK Mehta
Jan 1, 1993·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A MerloG C Spagnoli
Feb 1, 1994·Cancer·P RivaM Frattarelli
Citations
Apr 2, 2003·Journal of Immunological Methods·Alberto L HorensteinFabio Malavasi
Feb 5, 2003·Advanced Drug Delivery Reviews·Ying Cao, Laura Lam
Oct 11, 2003·Biotechnology Advances·A FunaroF Malavasi
Mar 16, 2011·Cell Research·Annalisa PezzoloVito Pistoia
May 22, 2001·Journal of Hematotherapy & Stem Cell Research·M SenL G Lum
Feb 26, 2013·BMC Cancer·Ian M ZitronSandeep Mittal
Nov 5, 2011·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Lawrence G Lum, Archana Thakur
Sep 1, 2008·Expert Opinion on Drug Discovery·Lawrence G Lum, Zaid Al-Kadhimi
Oct 9, 2007·Nuclear Medicine and Biology·C Andrew Boswell, Martin W Brechbiel
May 10, 2019·International Journal of Laboratory Hematology·Marie C Béné
Aug 24, 2017·Pharmacology & Therapeutics·Z Wu, N V Cheung